These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 14633830)
1. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients. Gallen IW; Carter C Diabetes Care; 2003 Dec; 26(12):3352-3. PubMed ID: 14633830 [No Abstract] [Full Text] [Related]
2. Studies show Lantus to be effective, safe and flexible in the treatment of type 1 diabetes. Walczak IM Diabetes Technol Ther; 2002; 4(5):744-5. PubMed ID: 12458569 [No Abstract] [Full Text] [Related]
3. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Harmel AP; Mathur R Diabetes Care; 2004 Jan; 27(1):272-3. PubMed ID: 14694001 [No Abstract] [Full Text] [Related]
4. Will the use of insulin analogs improve glycemic control during adolescence? Dunger DB Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260 [No Abstract] [Full Text] [Related]
5. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Albright ES; Desmond R; Bell DS Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268 [No Abstract] [Full Text] [Related]
6. Fasting and insulin glargine in individuals with type 1 diabetes. Mucha GT; Merkel S; Thomas W; Bantle JP Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549 [No Abstract] [Full Text] [Related]
7. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Lepore G; Dodesini AR; Nosari I; Trevisan R Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625 [No Abstract] [Full Text] [Related]
8. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Hathout EH; Fujishige L; Geach J; Ischandar M; Maruo S; Mace JW Diabetes Technol Ther; 2003; 5(5):801-6. PubMed ID: 14633345 [TBL] [Abstract][Full Text] [Related]
9. [Long acting insulin analogs: possibly more stable glucose regulation]. Huvers F Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1674-8. PubMed ID: 15453119 [TBL] [Abstract][Full Text] [Related]
11. FreeStyle navigator continuous glucose monitoring system use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group. Weinzimer S; Xing D; Tansey M; Fiallo-Scharer R; Mauras N; Wysocki T; Beck R; Tamborlane W; Ruedy K; Diabetes Care; 2008 Mar; 31(3):525-7. PubMed ID: 18096811 [TBL] [Abstract][Full Text] [Related]
13. The insulin analog glargine during an unplanned pregnancy. Cechurová D; Lacigová S; Jankovec Z; Haladová I; Zourek M; Krcma M; Rusavý Z; Turek J Wien Klin Wochenschr; 2006 Oct; 118(19-20):619-20. PubMed ID: 17136338 [No Abstract] [Full Text] [Related]
14. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Fulcher GR; Gilbert RE; Yue DK Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155 [TBL] [Abstract][Full Text] [Related]
15. 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications. Chatterjee S; Gallen IW; Sandler L Diabetes Care; 1999 Jul; 22(7):1226-7. PubMed ID: 10389002 [No Abstract] [Full Text] [Related]
16. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Hamann A; Matthaei S; Rosak C; Silvestre L; Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103 [TBL] [Abstract][Full Text] [Related]
17. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Davies M; Lavalle-González F; Storms F; Gomis R; Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327 [TBL] [Abstract][Full Text] [Related]
18. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543 [TBL] [Abstract][Full Text] [Related]
19. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088 [TBL] [Abstract][Full Text] [Related]
20. Insulin pump therapy for type 1 diabetes treatment in a girl with Down's syndrome. Scaramuzza AE; Giani E; Riboni S; Spiri D; De Palma A; Mameli C; Zuccotti GV Diabetes Res Clin Pract; 2009 Aug; 85(2):e16-8. PubMed ID: 19595363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]